Positive results from a study of ivacaftor (Kalydeco®) in children ages 1 to 2 were announced today.
Site Search
Two Phase 3 clinical trials of tezacaftor (VX-661) in combination with ivacaftor (Kalydeco®) showed positive results, Vertex Pharmaceuticals announced today.
Aim is to Provide Cystic Fibrosis Patients Enhanced Access to Medications and Expanded Pharmacy Services
The studies aim to improve early detection of chronic lung allograft dysfunction (CLAD), the leading cause of lung transplant failures.
Update: On February 3, 2017, the Cystic Fibrosis Foundation divested its remaining ownership stake in CF Services Inc., a specialty pharmacy. The pharmacy is now fully owned by Walgreens.
Today, the Cystic Fibrosis Foundation announced plans to improve lung transplantation for people with CF at an Organ Summit, hosted by the White House. The event focused on new and innovative ways to improve outcomes for individuals waiting for organ transplants and to improve support for living donors.
Piper Beatty, a two-time double-lung transplant recipient, testifies at an FDA meeting on organ transplantation.
The studies aim to improve our understanding of a common cause of lung transplant failures, a condition known as chronic lung allograft dysfunction (CLAD).